Longevity Through an Investor’s Lens

Where is the real cash flow, and what is still just a promise?

– By Áron Boros, CEO of Stradamus Zrt., which works closely with the Insiderlife.eu portal –

In brief: longevity is not a single industry but a collective name for business and research areas at very different stages of maturity. Lasting revenue is visible today mainly where a product treats a specific disease, supports a diagnostic decision or serves measurable consumer demand. Directly modifying the ageing process is still at an early clinical or preclinical stage.

In June 2026, NewLimit closed a $435 million Series C at a valuation of roughly $3.1 billion, while planning its first human trial for 2027. Oura, by contrast, reported revenue of $1.21 billion and net income of $60.8 million for the first nine months of 2026, with five million paying members. The company filed for an IPO in September, then postponed it at the end of the month. The two stories illustrate the duality of the sector: it contains both a proven business model and a long-term biological promise.

This article is an industry overview, not investment advice and not medical advice.

Why now?

For decades, longevity was the domain of research labs and a handful of tech billionaires. By 2026, four factors have matured at the same time, and together they explain why the topic is timely.

1. Paying demand has appeared. The developed world is ageing fast: according to UN projections, one in six people worldwide will be over 65 by 2050, and in the European Union that share already exceeds 21%. Even more important, wealth is concentrated in older age groups: according to Federal Reserve data, baby boomers held 51.6% of US household net worth in early 2026. At the same time, interest among people over 40 in extending their healthy years has risen sharply. This age group is noticing the first signs of ageing, has disposable income, and is willing to pay for prevention, measurement and preserving performance. In McKinsey’s 2025 survey, up to 60% of consumers in each market called healthy ageing a top priority. Longevity has thus moved from the lab to the consumer market: Oura’s five million paying members and the nearly three million subscribers of Hims & Hers are signs of the same demand.

2. Metabolic drugs delivered a commercial breakthrough. GLP-1-based products have proven that treating age-related metabolic disease can be a mass market worth tens of billions of dollars a year.

3. Health measurement has become cheaper and continuous. Wearables, continuous glucose monitoring, preventive lab panels and AI-based interpretation of data make it possible, for the first time, for users to get feedback on their health daily rather than yearly.

4. Longer-horizon capital has arrived. NewLimit’s $435 million round and the launch of Altos Labs with roughly $3 billion show that technology capital is ready to bet on decade-long payback horizons.

Four main segments

1. Metabolic drugs: this is where most of the money is today

The biggest commercial success of the longevity ecosystem so far has come not in an “anti-ageing” indication but in the treatment of obesity and type 2 diabetes. Global revenue of Eli Lilly’s Mounjaro was $9.94 billion in the second quarter of 2026, up 91% year on year; Zepbound brought in a further $4.93 billion. The regulatory reality is unchanged: the FDA does not approve drugs for a general “ageing” indication, so longevity biotech companies can reach the market only through specific diseases and validated clinical endpoints.

2. Consumer measurement and algorithms: scalable customer relationships

In the nine months to 30 June 2026, Oura generated $1.21 billion in revenue, up 74% year on year, and ended the period with five million paying members. About 80% of revenue still came from hardware, while subscriptions grew faster and carried a higher gross margin. Players such as Hume Health follow the same basic logic: hardware is the entry point, and the lasting value lies in the time series, the interpretation and customer retention. Risks include competition from tech giants, data privacy, and the fact that the claims of wellness devices are not the same as the clinical claims of a cleared medical device.

3. Preventive diagnostics and health subscriptions

In the second quarter of 2026, Hims & Hers generated $753.2 million in revenue, up 38% year on year, with 2.891 million subscribers. The company nevertheless reported a GAAP net loss of $86.3 million, while adjusted EBITDA remained positive. This illustrates the key question of the segment: customer acquisition and revenue growth alone are not enough; durable unit economics, medical quality and regulatory compliance must also be proven.

4. Cellular rejuvenation: the first clinical tests of a long promise

Altos Labs began operating in 2022 with roughly $3 billion in initial funding, yet it still has no publicly known clinical candidate. NewLimit plans its first human trial for 2027. In June 2026, Life Biosciences dosed the first patient with ER-100, a partial epigenetic reprogramming therapy; in October 2026 it reported early 56-day safety data from three glaucoma participants. These are encouraging but very early Phase 1 results from small patient numbers, and they do not yet demonstrate efficacy. The wind-down of Unity Biotechnology, meanwhile, is a reminder that a strong biological hypothesis does not guarantee clinical success.

Divisive frontiers: examples of “high risk, high reward”

Cryopreservation and organ preservation

Whole-body cryopreservation rests on the assumption that future technology will be able to repair damage that is irreversible today. There is no precedent for the successful revival of a human, so it cannot be regarded as a proven medical procedure or a mature investment category. From an investor’s perspective, a more rational and nearer-term market may be reversible organ and tissue preservation, which already solves an identifiable problem in transplantation, drug development and biobanking.

Brain-computer interfaces

Neuralink expanded its human programme quickly in 2026; public tallies in early October indicated at least 21 participants. The latest primary funding round in 2025 implied a valuation of roughly $9 billion, while secondary-market deals in 2026 showed a much higher range of $29–42 billion, and some later indications implied even higher values. These are not pricing points of the same quality: rare secondary transactions are no substitute for a price formed in a broad, liquid market.

The hungarian angle: Botond Roska and Katalin Karikó

Botond Roska

The founding director of the Institute of Molecular and Clinical Ophthalmology Basel and his colleagues use optogenetic methods to make still-functioning retinal cells light-sensitive when the natural photoreceptors have already been damaged. In 2021, the research group reported in Nature Medicine the partial restoration of visual function in a patient with retinitis pigmentosa. In 2026, Roska and José-Alain Sahel jointly received the €1 million António Champalimaud Vision Award. The link to longevity is indirect but professionally relevant: it exemplifies treatable targets for age-related loss of function and the clinical translation of regenerative neuroscience.

Katalin Karikó

The work of Katalin Karikó and Drew Weissman showed that the inflammatory effect of nucleoside-modified mRNA can be reduced, which laid the foundation for the therapeutic use of mRNA. mRNA allows short-lived, controllable protein production, so in principle it could also suit reprogramming strategies where sustained expression of transcription factors would be risky. This is not evidence that Karikó’s research is directly developing a partial epigenetic reprogramming therapy, but the possibility is there. Her current research focus includes mRNA therapeutics, protein replacement and certain neurodegenerative mechanisms related to RNA toxicity.

Cash flow or promise?

Segment	Revenue today	Maturity	Investment risk
Metabolic drugs	Tens of billions of USD a year	Commercial	Medium
Consumer measurement	Above USD 1 billion for the leaders	Early commercial	Medium-high
Diagnostics, subscriptions	USD 100 million to 1 billion	Early commercial	High
Cellular rejuvenation	No meaningful product revenue	Phase 1 / preclinical	Very high
Cryopreservation	Small, niche	Experimental service	Very high
Brain-computer interfaces	Minimal	Early clinical	Very high

Risks and the €10,000 framework

The growth of an industry and shareholder returns are two separate questions. The main risks are binary clinical outcomes, long development cycles, capital needs and dilution, regulatory change, data privacy, product liability, concentrated competition and private-market illiquidity. The capital invested may be lost in part or in full.

€10,000 is an upper limit, not a target amount. Within a conservative framework, only the following can be justified: money you can do without, a small fraction of total liquid wealth, diversification across several issuers and segments, staggered entry over time, and a horizon of at least ten years. On individual suitability and product selection, only a licensed investment adviser can give a personalised opinion.

Market map

Without claiming to be exhaustive, here is which company entry points are worth putting on the map today. Listed, related players include, for example: Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), BioAge Labs (Nasdaq: BIOA), Dexcom (Nasdaq: DXCM), Abbott Laboratories (NYSE: ABT), Hims & Hers Health (NYSE: HIMS) and Quest Diagnostics (NYSE: DGX). Oura postponed its IPO in September 2026, so at the time of writing it is not tradable as a Nasdaq-listed stock. Altos Labs, NewLimit, Life Biosciences, Function Health, Hume Health, Tomorrow Bio, Neuralink and Synchron are private companies.

As can be seen, the public market is still quite narrow from an investor’s point of view, and investing in private companies is possible mainly through venture capital funds.

Disclosures and legal notice

Interests:

The author is a member of the board of directors of Remedium Asset Management; the asset manager is preparing to launch a longevity-focused venture capital fund. This article does not constitute marketing of the fund.

Legal notice:

This article is general industry information and the author’s sector-level opinion. It does not constitute investment advice, a personalised recommendation, investment research or an investment recommendation within the meaning of Regulation (EU) No 596/2014. It contains no buy, hold or sell recommendation, price target or valuation. Past data are not a reliable indicator of future performance. Nor does the article constitute medical advice.